OncoMatch/Clinical Trials/NCT07491445
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Is NCT07491445 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including daraxonrasib and gemcitabine for pancreatic cancer.
Treatment: daraxonrasib · gemcitabine · nab-paclitaxel — The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Allowed: HRAS any mutation
Allowed: HRAS wild-type
Allowed: KRAS any mutation
Allowed: KRAS wild-type
Allowed: NRAS any mutation
Allowed: NRAS wild-type
Disease stage
Required: Stage IV
Metastatic disease required
Diagnosis of metastatic disease 6 weeks prior to informed consent
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Exception: adjuvant/neoadjuvant therapy not mentioned
Prior treatment with systemic anticancer therapy in metastatic setting
Cannot have received: RAS-targeted therapy
prior RAS-targeted therapy in any treatment setting
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Comprehensive Cancer Centers of Nevada · Henderson, Nevada
- Taylor Cancer Research Center · Maumee, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify